Incidence and Predictors of XXXX After Primary Percutaneous Coronary Intervention for Anterior ST-Segment Elevation @entity583 .

@entity1 @entity548 @entity1229 @entity117 @entity1167 @entity583 @entity1455 @entity715 @entity1002
BACKGROUND: The role of @entity1229 in anterior @entity583 ( @entity583 ) complicated by @entity1002 in @entity1 treated with primary percutaneous coronary intervention (PCI) and dual antiplatelet therapy is unclear. @entity1229 may prevent cardioembolic events but significantly increases @entity548 in the setting of dual antiplatelet therapy. HYPOTHESIS: The incidence of LV @entity715 in anterior @entity583 @entity1 treated with PCI is low, and clinical predictors might be valuable in determining @entity1 at risk. METHODS: We performed a retrospective, single-center study of 687 consecutive @entity1 with anterior @entity583 treated with PCI from 2006 to 2013. Baseline variables were evaluated in 310 @entity1 at high risk for LV @entity715 based on echocardiographic criteria. @entity1 with definite, probable, and no LV @entity715 were compared by ANOVA,   (2) , or t test where appropriate. Logistic regression analysis was performed. RESULTS: The incidence of LV @entity715 was 15% (n   =   47 probable/definite @entity715 ). @entity1167 was the only independent characteristic associated with increased risk of LV @entity715 (odds ratio [OR]: 4.06, 95% confidence interval [CI]: 1.3-12.7). Trends were observed for a lower risk in @entity1455 (OR: 0.33, 95% CI: 0.10-1.05) and @entity117 use at baseline (OR: 0.43, 95% CI: 0.17-1.1). Treatment variables associated with LV @entity715 included unfractionated heparin use post-PCI (OR: 2.43, 95% CI: 1.16-5.1) and use of balloon angioplasty without stent. CONCLUSIONS: In contemporary practice with primary PCI, definite LV @entity715 following anterior @entity583 with @entity1002 is challenging to predict. Further investigation is needed to determine if there is a subset of @entity1 that should be treated with prophylactic @entity1229 .
